Andreas Bohrer has served as Lonza’s Group General Counsel and Company Secretary since 2015 As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal & Corporate Affairs Officer ...

PORTSMOUTH — ApprenticeshipNH, the workforce training program of the Community College System of New Hampshire, has partnered with Lonza to launch a new apprenticeship program at the company’s ...

There are limited tariff risks. Lonza is a potential beneficiary given the ample availability of the USA industrial capacities should biotech or pharma have onshoring needs. With profit growth ...

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly formed CDMO Business ...

Lonza Group AG has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ingredients business, according to people familiar with the matter, as part ...

Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about $7 ...

Approaching his 200th day as the new Chief Executive Officer of Lonza, Wolfgang Wienand discussed the company’s plans to exit the Capsules and Health Ingredients (CHI) business and concentrate ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing ...

Wolfgang Wienand, who joined Lonza as CEO in July, has begun to put his stamp on the Swiss drug services company. Lonza announced at an investor event that it plans to divest its Capsules and ...

Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing and jettisoning less profitable areas of its operations. During an ...

Lonza shares rise 6.7% after CHI exit announcement Company to focus on CDMO business restructuring Plans M&A for tech and capacity opportunities Dec 12 (Reuters) - Swiss contract drugmaker Lonza ...